Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) Share Price

Company Profile

Business description
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
Contact
12 Baoshen South Street
Daxing Bio-Medicine Industry Park
Daxing District
Beijing
CHN
T: +86 1056967680
https://www.biocytogen.com.cn
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,117

Recommended

As investors toil in complexity the obvious solution may be the right one.

Mark LaMonica, CFA | 24 July 2025

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.

Matthew Dolgin, CFA | 23 July 2025

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.

John Abernethy | 23 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,934.30	45.10	-0.50%
CAC 40	7,834.58	16.30	0.21%
DAX 40	24,217.50	78.43	-0.32%
Dow JONES (US)	44,901.92	208.01	0.47%
FTSE 100	9,120.31	18.06	-0.20%
HKSE	25,388.35	278.83	-1.09%
NASDAQ	21,108.32	50.36	0.24%
Nikkei 225	41,456.23	370.11	-0.88%
NZX 50 Index	12,853.46	48.33	0.38%
S&P 500	6,388.64	25.29	0.40%
S&P/ASX 200	8,666.90	42.50	-0.49%
SSE Composite Index	3,593.66	12.07	-0.33%